Female adolescents and young women previously treated for pediatric malignancies: assessment of ovarian reserve and gonadotoxicity risk stratification for early identification of patients at increased infertility risk.
Adolescent
Anti-Mullerian Hormone
/ metabolism
Antineoplastic Agents
/ adverse effects
Cancer Survivors
/ statistics & numerical data
Child
Child, Preschool
Female
Follicle Stimulating Hormone
/ metabolism
Follow-Up Studies
Humans
Infant
Infertility, Female
/ etiology
Neoplasms
/ drug therapy
Ovarian Reserve
Prognosis
Reproduction
Retrospective Studies
Risk Assessment
/ methods
anti-m|llerian hormone
antral follicle count
gonadotoxicity risk
ovarian reserve
premature ovarian insufficiency
young childhood cancer survivors
Journal
Journal of pediatric endocrinology & metabolism : JPEM
ISSN: 2191-0251
Titre abrégé: J Pediatr Endocrinol Metab
Pays: Germany
ID NLM: 9508900
Informations de publication
Date de publication:
27 Jan 2021
27 Jan 2021
Historique:
received:
14
05
2020
accepted:
31
08
2020
pubmed:
18
10
2020
medline:
21
10
2021
entrez:
17
10
2020
Statut:
epublish
Résumé
Childhood and adolescent cancer survivors (CACSs) are at risk of adverse reproductive outcomes. Assessment of follicle-stimulating hormone (FSH) levels is the most common test used to diagnose premature ovarian insufficiency (POI) whereas anti-m|llerian hormone (AMH) and antral follicle count (AFC) have been proposed as ovarian reserve markers. We assessed the correlation between these markers and treatment gonadotoxicity risk (GR) in CACSs. A total of 55 female CACSs were enrolled. GR was graded as low, medium, or high according to classifications based on disease and treatments and on cyclophosphamide equivalent dose score. FSH, AMH, and AFC were determined. POI was defined by amenorrhea and FSH>30 IU/L. For remaining patients, diminished ovarian reserve (DOR) was defined by AMH<5th centile. FSH and AFC cut-offs proposed in the literature as DOR markers were also considered (FSH>10 IU/L or >95th centile; AFC<8 or <5th centile). Ovarian reserve results to be compromised in 23 (41.8%) patients: 14 with DOR and 9 with an established POI. Results showed GR classifications to be a good predictor of ovarian reserve, with significantly lower AMH and AFC in the high-risk groups. AFC resulted to be directly correlated with AMH (r=0.75, p<0.001). In CACSs, GR classifications correlate with post-treatment AMH and AFC. These are useful tools in the early identification of young patients with DOR, who may benefit from reproductive and fertility preservation counseling. Further studies are needed to determine the rate and time of progression from DOR to POI in this population.
Identifiants
pubmed: 33068384
doi: 10.1515/jpem-2020-0272
pii: /j/jpem.ahead-of-print/jpem-2020-0272/jpem-2020-0272.xml
doi:
Substances chimiques
Antineoplastic Agents
0
Anti-Mullerian Hormone
80497-65-0
Follicle Stimulating Hormone
9002-68-0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
25-33Informations de copyright
© 2020 Walter de Gruyter GmbH, Berlin/Boston.
Références
ACOG Committee Opinion No. 747. Summary: gynecologic issues in children and adolescent cancer patients and survivors. Obstet Gynecol 2018;132:535-6. https://doi.org/10.1097/AOG.0000000000002764.
Cancer Statistics ReviewSEER statistics; 1975-2014 SEER n.d. Available from: https://seer.cancer.gov/archive/csr/1975_2014/ [Accessed 16 Dec 2019].
van Dorp, W, Mulder, RL, Kremer, LCM, Hudson, MM, van den Heuvel-Eibrink, MM, van den Berg, MH, et al. Recommendations for premature ovarian insufficiency surveillance for female survivors of childhood, adolescent, and young adult cancer: a report from the international late effects of childhood cancer guideline harmonization group in collaboration with the pancaresurfup consortium. J Clin Oncol 2016;34:3440-50https://dx.doi.org/10.1200%2FJCO.2015.64.3288.
van Dorp, W, Haupt, R, Anderson, RA, Mulder, RL, van den Heuvel-Eibrink, MM, van Dulmen-den Broeder, E, et al. Reproductive function and outcomes in female survivors of childhood, adolescent, and young adult cancer: a review. J Clin Oncol 2018;36:2169-80https://dx.doi.org/10.1200%2FJCO.2017.76.3441.
Levine, JM, Whitton, JA, Ginsberg, JP, Green, DM, Leisenring, WM, Stovall, M, et al. Nonsurgical premature menopause and reproductive implications in survivors of childhood cancer: a report from the childhood cancer survivor study. Cancer 2018;124:1044-52. https://doi.org/10.1002/cncr.31121.
Chemaitilly, W, Li, Z, Krasin, MJ, Brooke, RJ, Wilson, CL, Green, DM, et al. Premature ovarian insufficiency in childhood cancer survivors: a report from the St. Jude lifetime cohort. J Clin Endocrinol Metab 2017;102:2242-50. https://doi.org/10.1210/jc.2016-3723.
Wallace, WHB, Anderson, RA, Irvine, DS. Fertility preservation for young patients with cancer: who is at risk and what can be offered? Lancet Oncol 2005;6:209-18. https://doi.org/10.1016/S1470-2045(05)70092-9.
Anderson, RA, Wallace, WHB. Antim|llerian hormone, the assessment of the ovarian reserve, and the reproductive outcome of the young patient with cancer. Fertil Steril 2013;99:1469-75. https://doi.org/10.1016/j.fertnstert.2013.03.014.
Algarroba, GN, Sanfilippo, JS, Valli-Pulaski, H. Female fertility preservation in the pediatric and adolescent cancer patient population. Best Pract Res Clin Obstet Gynaecol 2018;48:147-57. https://doi.org/10.1016/j.bpobgyn.2017.10.009.
Overbeek, A, van den Berg, MH, van Leeuwen, FE, Kaspers, GJL, Lambalk, CB, van Dulmen-den Broeder, E. Chemotherapy-related late adverse effects on ovarian function in female survivors of childhood and young adult cancer: a systematic review. Canc Treat Rev 2017;53:10-24. https://doi.org/10.1016/j.ctrv.2016.11.006.
Green, DM, Nolan, VG, Goodman, PJ, Whitton, JA, Srivastava, D, Leisenring, WM, et al. The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure: a report from the childhood cancer survivor study. Pediatr Blood Canc 2014;61:53-67. https://doi.org/10.1002/pbc.24679.
La Marca, A, Sunkara, SK. Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. Hum Reprod Update 2014;20:124-40. https://doi.org/10.1093/humupd/dmt037.
Wiweko, B, Prawesti, DMP, Hestiantoro, A, Sumapraja, K, Natadisastra, M, Baziad, A. Chronological age vs. biological age: an age-related normogram for antral follicle count, FSH and anti-mullerian hormone. J Assist Reprod Genet 2013;30:1563-7. https://doi.org/10.1007/s10815-013-0083-1.
Peqarrubia, J, Fabregues, F, Manau, D, Creus, M, Casamitjana, R, Carmona, F, et al. Initial analysis of variability among basal hormone biomarkers of ovarian reserve. Reprod Biomed Online 2004;8:191-5. https://doi.org/10.1016/S1472-6483(10)60515-9.
Elchuri, SV, Patterson, BC, Brown, M, Bedient, C, Record, E, Wasilewski-Masker, K, et al. Low anti-m|llerian hormone in pediatric cancer survivors in the early years after gonadotoxic therapy. J Pediatr Adolesc Gynecol 2016;29:393-9. https://doi.org/10.1016/j.jpag.2016.02.009.
La Marca, A, Spada, E, Grisendi, V, Argento, C, Papaleo, E, Milani, S, et al. Normal serum anti-m|llerian hormone levels in the general female population and the relationship with reproductive history. Eur J Obstet Gynecol Reprod Biol 2012;163:180-4. https://doi.org/10.1016/j.ejogrb.2012.04.013.
Lie Fong, S, Visser, JA, Welt, CK, de Rijke, YB, Eijkemans, MJC, Broekmans, FJ, et al. Serum anti-m|llerian hormone levels in healthy females: a nomogram ranging from infancy to adulthood. J Clin Endocrinol Metab 2012;97:4650-5. https://doi.org/10.1210/jc.2012-1440.
Ferraretti, AP, La Marca, A, Fauser, BCJM, Tarlatzis, B, Nargund, G, Gianaroli, L, et al. ESHRE consensus on the definition of "poor response" to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod 2011;26:1616-24. https://doi.org/10.1093/humrep/der092.
van der Steeg, JW, Steures, P, Eijkemans, MJC, Habbema, JDF, Hompes, PGA, Broekmans, FJ, et al. Predictive value and clinical impact of basal follicle-stimulating hormone in subfertile, ovulatory women. J Clin Endocrinol Metab 2007;92:2163-8. https://doi.org/10.1210/jc.2006-2399.
Grisendi, V, Spada, E, Argento, C, Plebani, M, Milani, S, Seracchioli, R, et al. Age-specific reference values for serum FSH and estradiol levels throughout the reproductive period. Gynecol Endocrinol 2014;30:451-5. https://doi.org/10.3109/09513590.2014.893572.
La Marca, A, Spada, E, Sighinolfi, G, Argento, C, Tirelli, A, Giulini, S, et al. Age-specific nomogram for the decline in antral follicle count throughout the reproductive period. Fertil Steril 2011;95:684-8. https://doi.org/10.1016/j.fertnstert.2010.07.1069.
Chung, MK. Correlation coefficient. In: Salkin, NJ, editor. Encyclopedia of measurement and statistics. London: Sage Publications; 2007.
van den Berg, MH, Overbeek, A, Lambalk, CB, Kaspers, GJL, Bresters, D, van den Heuvel-Eibrink, MM, et al. Long-term effects of childhood cancer treatment on hormonal and ultrasound markers of ovarian reserve. Hum Reprod 2018;33:1474-88. https://doi.org/10.1093/humrep/dey229.
Lie Fong, S, Laven, JSE, Hakvoort-Cammel, FG, Schipper, I, Visser, JA, Themmen, APN, et al. Assessment of ovarian reserve in adult childhood cancer survivors using anti-m|llerian hormone. Hum Reprod 2009;24:982-90. https://doi.org/10.1093/humrep/den487.
George, SA, Williamson Lewis, R, Schirmer, DA, Effinger, KE, Spencer, JB, Mertens, AC, et al. Early detection of ovarian dysfunction by anti-mullerian hormone in adolescent and young adult-aged survivors of childhood cancer. J Adolesc Young Adult Oncol 2019;8:18-25. https://doi.org/10.1089/jayao.2018.0080.
Lunsford, AJ, Whelan, K, McCormick, K, McLaren, JF. Antim|llerian hormone as a measure of reproductive function in female childhood cancer survivors. Fertil Steril 2014;101:227-31. https://doi.org/10.1016/j.fertnstert.2013.08.052.
Streuli, I, Fraisse, T, Pillet, C, Ibecheole, V, Bischof, P, de Ziegler, D. Serum antim|llerian hormone levels remain stable throughout the menstrual cycle and after oral or vaginal administration of synthetic sex steroids. Fertil Steril 2008;90:395-400. https://doi.org/10.1016/j.fertnstert.2007.06.023.
Lambert-Messerlian, G, Plante, B, Eklund, EE, Raker, C, Moore, RG. Levels of antim|llerian hormone in serum during the normal menstrual cycle. Fertil Steril 2016;105:208-13 e1. https://doi.org/10.1016/j.fertnstert.2015.09.033.
Hehenkamp, WJK, Looman, CWN, Themmen, APN, de Jong, FH, Te Velde, ER, Broekmans, FJM. Anti-m|llerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation. J Clin Endocrinol Metab 2006;91:4057-63. https://doi.org/10.1210/jc.2006-0331.
Practice Committee of the American Society for Reproductive Medicine Diagnostic evaluation of the infertile female: a committee opinion. Fertil Steril 2015;103:e44-50. https://doi.org/10.1016/j.fertnstert.2015.03.019.
Waaseth, M, Bakken, K, Dumeaux, V, Olsen, KS, Rylander, C, Figenschau, Y, et al. Hormone replacement therapy use and plasma levels of sex hormones in the Norwegian women and cancer postgenome cohort - a cross-sectional analysis. BMC Wom Health 2008;8:1. https://doi.org/10.1186/1472-6874-8-1.
van Santen, HM, van den Heuvel-Eibrink, MM, van de Wetering, MD, Wallace, WH. Hypogonadism in children with a previous history of cancer: endocrine management and follow-up. Horm Res Paediatr 2019;91:93-103. https://doi.org/10.1159/000495943.
Nystrvm, A, Mvrse, H, Nordlvf, H, Wiebe, K, Artman, M, Xra, I, et al. Anti-m|llerian hormone compared with other ovarian markers after childhood cancer treatment. Acta Oncol 2019;58:218-24. https://doi.org/10.1080/0284186X.2018.1529423.
Teede, HJ, Misso, ML, Costello, MF, Dokras, A, Laven, J, Moran, L, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod 2018;33:1602-18. https://doi.org/10.1093/humrep/dey256.
Coelho Neto, MA, Ludwin, A, Borrell, A, Benacerraf, B, Dewailly, D, da Silva Costa, F, et al. Counting ovarian antral follicles by ultrasound: a practical guide. Ultrasound Obstet Gynecol 2018;51:10-20. https://doi.org/10.1002/uog.18945.
Frobisher, C, Glaser, A, Levitt, GA, Cutter, DJ, Winter, DL, Lancashire, ER, et al. Risk stratification of childhood cancer survivors necessary for evidence-based clinical long-term follow-up. Br J Canc 2017;117:1723-31. https://doi.org/10.1038/bjc.2017.347.
Kutteh, WH, Klosky, JL, Green, DM, Sparrow, CK, Kutteh, MA, Robinson, GW, et al. Ovulation induction and oocyte retrieval for fertility preservation in young adolescents newly diagnosed with medulloblastoma: a case series. J Obstet Gynaecol 2018;38:878-9. https://doi.org/10.1080/01443615.2017.1398222.
Group, CO. Long-term follow-up guidelines for survivors of childhood, adolescent, and young adult cancers 2008. Version 3.0. http://WwwSurvivor-ShipguidelinesOrg/.
Roeca, C, Dovey, S, Polotsky, AJ. Recommendations for assessing ovarian health and fertility potential in survivors of childhood cancer. Maturitas 2019;122:57-9. https://doi.org/10.1016/j.maturitas.2019.01.009.
Morin, SJ, Patounakis, G, Juneau, CR, Neal, SA, Scott, RTJr, Seli, E. Diminished ovarian reserve and poor response to stimulation in patients <38 years old: a quantitative but not a qualitative reduction in performance. Hum Reprod 2018;33:1489-98. https://doi.org/10.1093/humrep/dey238.